CELLULAR AND HUMORAL IMMUNE RESPONSES IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA AFTER VACCINATION WITH ANTIGEN PULSED DENDRITIC CELLS
Authors:
- 1 March 1999
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 161 (3) , 777-782
Abstract
Conclusions Our data demonstrate that a dendritic cell based vaccine can induce antigen specific immunity in patients with metastatic renal cell carcinoma. Dendritic cell based immunotherapy represents a feasible, well tolerated and promising new approach for the treatment of advanced renal cell carcinoma.Keywords
This publication has 17 references indexed in Scilit:
- CD83+ blood dendritic cells as a vaccine for immunotherapy of metastatic renal-cell cancerThe Lancet, 1998
- Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA)The Prostate, 1998
- ACTIVATION OF HUMAN DENDRITIC CELLS BY BACILLUS CALMETTE-GUERINJournal of Urology, 1998
- Dendritic cells and the control of immunityNature, 1998
- Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cellsNature Medicine, 1998
- Treatment of Metastatic Renal Cell Carcinoma With Nephrectomy, Interleukin-2 and Cytokine-Primed or CD8(+) Selected Tumor Infiltrating Lymphocytes from Primary TumorJournal of Urology, 1997
- Dendritic Cells for the Immunotherapy of Renal Cell CarcinomaUrologia Internationalis, 1997
- Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation.Journal of Experimental Medicine, 1996
- Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cellsNature Medicine, 1996
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987